Study of Telemedicine-Guided Therapy Adjustment Versus Standard Care in Adults with Newly Diagnosed Heart Failure with Reduced Ejection Fraction

What this Trial Is About

Researchers are evaluating a telemedicine-based follow-up strategy compared with standard in-person care for patients newly diagnosed with heart failure with reduced ejection fraction HFrEF. The study aims to see if telemedicine can improve the optimization of guideline-directed medical therapy GDMT over six months. This trial focuses on early treatment improvements during a high-risk period after hospital discharge, seeking to enhance clinical management and patient outcomes in real-world settings. Participants will be randomly assigned to one of two groups. The telemedicine group will receive an early structured consultation after discharge supported by remote monitoring of vital signs such as blood pressure, heart rate, oxygen levels, body weight, and heart rhythm via single-lead electrocardiogram. This allows early reassessment and timely adjustment of heart failure medications. The comparison group will have standard care with in-person follow-ups and GDMT optimization as per usual clinical practice. During the study, participants will undergo regular assessments of medication adherence, quality of life, and patient satisfaction using validated questionnaires. Researchers will monitor clinical events like hospital visits related to heart failure and assess safety through tracking kidney function, potassium levels, and blood pressure symptoms. The studys main outcome is the change in GDMT score from baseline to 6 months, reflecting medication initiation and dose increases. The total study duration and follow-up are designed to provide comprehensive data on the effectiveness and safety of telemedicine in managing HFrEF.

Telemedicine-guided Uptitration of Therapy in Chronic Heart Failure